GENB
insider transactionsGenerate Biomedicines, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Cluster buy signal: Multiple insiders at the same company buying around the same time — often a stronger signal than a single buy. 4 different insiders made open-market purchases in the last 365 days, totalling $292.8K.
Net shares · 365d
+23.3K
23.3K buy · 0 sell
Net value · 365d
$292.8K
$292.8K in · $0 out
Sentiment · 365d
Net buying
100% buying · 0% selling
Open-market trades · 365d
5
23.3K buy · 0 sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Buy·P
Michael Nally KEY
Chief Executive Officer
$240.0K
20.0K sh · $12.00
Own +4%
-
Buy·P
Chief People Officer
$4.8K
300 sh · $16.00
Own New
-
Buy·P
Jason Silvers KEY
President & CFO
$16.0K
1.0K sh · $16.00
Own New
-
Buy·P
Jason Silvers KEY
President & CFO
$8.0K
500 sh · $16.00
Own New
-
Exercise·C
Michael Nally KEY
Chief Executive Officer
$0
1.0M sh
Own New
-
Exercise·C
Michael Nally KEY
Chief Executive Officer
—
658.3K sh
Own +100%
-
Buy·P
Director
$24.0K
1.5K sh · $16.00
Own New
-
Exercise·C
Director
$0
1.1M sh
Own New
-
Exercise·C
Director
—
724.2K sh
Own New
-
Grant·A
Stephane Bancel KEY
Chief Executive Officer
$0
250.9K sh
Own New
-
Grant·A
Director
$0
29.6K sh
Own New
-
Grant·A
Chief People Officer
$0
114.0K sh
Own New
-
Grant·A
Chief Medical Officer
$0
42.2K sh
Own New
-
Grant·A
Chief Legal Officer & GC
$0
190.0K sh
Own New
-
Grant·A
Director
$0
29.6K sh
Own New
-
Grant·A
Jason Silvers KEY
President & CFO
$0
274.5K sh
Own New
-
Grant·A
Jason Silvers KEY
President & CFO
$0
295.6K sh
Own New
-
Grant·A
Chief Technology Officer
$0
196.4K sh
Own New
-
Grant·A
Chief Technology Officer
$0
295.6K sh
Own New
-
Grant·A
Michael Nally KEY
Chief Executive Officer
$0
844.6K sh
Own New
-
Grant·A
Director
$0
29.6K sh
Own New
-
Grant·A
Director
$0
29.6K sh
Own New
-
Grant·A
Director
$0
29.6K sh
Own New
-
Grant·A
Director
$0
29.6K sh
Own New
-
Other·F
Stephane Bancel KEY
Chief Executive Officer
$228.8K
5.5K sh · $41.99
Own -0%
-
Grant·A
Stephane Bancel KEY
Chief Executive Officer
$0
11.3K sh
Own +0%
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Mar 4, 2026 | Michael Nally KEY | Buy P | 20.0K | $240.0K |
| Mar 2, 2026 | Beth Grous | Buy P | 300 | $4.8K |
| Mar 2, 2026 | Jason Silvers KEY | Buy P | 1.0K | $16.0K |
| Mar 2, 2026 | Jason Silvers KEY | Buy P | 500 | $8.0K |
| Mar 2, 2026 | Michael Nally KEY | Exercise C | 1.0M | $0 |
| Mar 2, 2026 | Michael Nally KEY | Exercise C | 658.3K | — |
| Mar 2, 2026 | Jane L Mendillo | Buy P | 1.5K | $24.0K |
| Mar 2, 2026 | Stephane Bancel | Exercise C | 1.1M | $0 |
| Mar 2, 2026 | Stephane Bancel | Exercise C | 724.2K | — |
| Mar 1, 2026 | Stephane Bancel KEY | Grant A | 250.9K | $0 |
| Feb 26, 2026 | Rupert Vessey | Grant A | 29.6K | $0 |
| Feb 26, 2026 | Beth Grous | Grant A | 114.0K | $0 |
| Feb 26, 2026 | Laurie Anne Lee | Grant A | 42.2K | $0 |
| Feb 26, 2026 | Sean Martin | Grant A | 190.0K | $0 |
| Feb 26, 2026 | Nancy A Simonian | Grant A | 29.6K | $0 |
| Feb 26, 2026 | Jason Silvers KEY | Grant A | 274.5K | $0 |
| Feb 26, 2026 | Jason Silvers KEY | Grant A | 295.6K | $0 |
| Feb 26, 2026 | Gevorg Grigoryan | Grant A | 196.4K | $0 |
| Feb 26, 2026 | Gevorg Grigoryan | Grant A | 295.6K | $0 |
| Feb 26, 2026 | Michael Nally KEY | Grant A | 844.6K | $0 |
| Feb 26, 2026 | Jane L Mendillo | Grant A | 29.6K | $0 |
| Feb 26, 2026 | Paul Gray Parker | Grant A | 29.6K | $0 |
| Feb 26, 2026 | Marsha Fanucci | Grant A | 29.6K | $0 |
| Feb 26, 2026 | Stephane Bancel | Grant A | 29.6K | $0 |
| Feb 11, 2026 | Stephane Bancel KEY | Other F | 5.5K | $228.8K |
| Feb 11, 2026 | Stephane Bancel KEY | Grant A | 11.3K | $0 |
About GENB insider trading
This page tracks insider transactions for Generate Biomedicines, Inc. (GENB) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.